Kalaris Therapeutics Incorporation Registered shs Aktie
WKN DE: A40YEN / ISIN: US4829291065
|
03.11.2025 15:07:31
|
Kalaris Therapeutics Appoints Matthew Gall CFO
(RTTNews) - Kalaris Therapeutics, Inc. (KLRS), a biopharmaceutical company, Monday announced that it has appointed Matthew Gall, as its chief financial officer.
Most recently, Gall was the finance chief of iTeos Therapeutics, and prior to iTeos he held positions at Sarepta Therapeutics, Celgene Corporation, and Gilead Sciences across the finance and business development functions.
In pre-market activity, Kalaris shares are trading at $5.45, up 8.35% on the Nasdaq.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Kalaris Therapeutics Incorporation Registered shsmehr Nachrichten
| Keine Nachrichten verfügbar. |